Found: 5
Select item for more details and to access through your institution.
Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy‐related myelodysplastic syndromes.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 4, p. 713, doi. 10.1111/bjh.18319
- By:
- Publication type:
- Article
Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
- Published in:
- Therapeutic Advances in Hematology, 2021, v. 12, p. 1, doi. 10.1177/2040620720986641
- By:
- Publication type:
- Article
Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 7, p. 459, doi. 10.1016/j.clml.2024.03.001
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 3, p. 168, doi. 10.1016/j.clml.2023.01.001
- By:
- Publication type:
- Article
Myelodysplastic Syndromes: A New Decade.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 1, p. 1, doi. 10.1016/j.clml.2021.07.031
- By:
- Publication type:
- Article